Philip Astley-Sparke Sells 6,460 Shares of Uniqure NV (NASDAQ:QURE) Stock

Share on StockTwits

Uniqure NV (NASDAQ:QURE) Director Philip Astley-Sparke sold 6,460 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $60.12, for a total transaction of $388,375.20. Following the completion of the sale, the director now owns 12,406 shares of the company’s stock, valued at $745,848.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Philip Astley-Sparke also recently made the following trade(s):

  • On Monday, June 3rd, Philip Astley-Sparke sold 6,000 shares of Uniqure stock. The stock was sold at an average price of $63.63, for a total transaction of $381,780.00.

Uniqure stock opened at $56.61 on Thursday. Uniqure NV has a 1-year low of $21.98 and a 1-year high of $82.49. The company has a market capitalization of $2.15 billion, a price-to-earnings ratio of -24.19 and a beta of 0.94. The firm has a fifty day simple moving average of $70.48. The company has a debt-to-equity ratio of 0.51, a current ratio of 8.07 and a quick ratio of 8.07.

Uniqure (NASDAQ:QURE) last released its quarterly earnings data on Monday, July 29th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.08). Uniqure had a negative net margin of 1,232.30% and a negative return on equity of 61.67%. The business had revenue of $2.47 million during the quarter, compared to the consensus estimate of $1.53 million. As a group, sell-side analysts forecast that Uniqure NV will post -3.18 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. Harvest Group Wealth Management LLC bought a new position in shares of Uniqure in the first quarter valued at $26,000. Pearl River Capital LLC bought a new position in shares of Uniqure in the first quarter valued at $32,000. Legal & General Group Plc lifted its stake in shares of Uniqure by 264.2% in the fourth quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 700 shares in the last quarter. Botty Investors LLC bought a new position in shares of Uniqure in the second quarter valued at $78,000. Finally, Aperio Group LLC bought a new position in shares of Uniqure in the second quarter valued at $83,000. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

QURE has been the subject of a number of research reports. Janney Montgomery Scott restated a “buy” rating on shares of Uniqure in a report on Tuesday, June 11th. BidaskClub cut shares of Uniqure from a “sell” rating to a “strong sell” rating in a report on Thursday. HC Wainwright set a $73.00 price target on shares of Uniqure and gave the stock a “buy” rating in a report on Monday, July 8th. Zacks Investment Research cut shares of Uniqure from a “buy” rating to a “hold” rating in a report on Friday, August 2nd. Finally, Guggenheim cut shares of Uniqure from a “buy” rating to a “neutral” rating in a report on Monday, July 29th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the stock. Uniqure presently has an average rating of “Buy” and an average price target of $78.18.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Featured Story: What is the Moving Average Convergence Divergence (MACD) oscillator?

Insider Buying and Selling by Quarter for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Swiss National Bank Buys 4,900 Shares of ChannelAdvisor Corp
Swiss National Bank Buys 4,900 Shares of ChannelAdvisor Corp
Doheny Asset Management CA Buys 960 Shares of AT&T Inc.
Doheny Asset Management CA Buys 960 Shares of AT&T Inc.
Doheny Asset Management CA Buys 2,865 Shares of Xilinx, Inc.
Doheny Asset Management CA Buys 2,865 Shares of Xilinx, Inc.
$1.31 EPS Expected for Microchip Technology Inc.  This Quarter
$1.31 EPS Expected for Microchip Technology Inc. This Quarter
Doheny Asset Management CA Has $387,000 Stock Holdings in Lowe’s Companies, Inc.
Doheny Asset Management CA Has $387,000 Stock Holdings in Lowe’s Companies, Inc.
-$0.63 Earnings Per Share Expected for Instructure Inc  This Quarter
-$0.63 Earnings Per Share Expected for Instructure Inc This Quarter


© 2006-2019 Ticker Report